“The problem with the Alzheimer’s group is they were very co-opted,” said Peter J. Whitehouse, MD, PhD, a professor of ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Wafaa Mamilli (1967) will join the company as Chief Digital ...

Minnesota Attorney General Keith Ellison announced a settlement with pharmaceutical company Norvo Nordisk over allegations of ...

Telehealth company Hims & Hers is playing offense in a new commercial slated to air during the Super Bowl next month. | Telehealth company Hims & Hers is playing offense in a new commercial slated to ...

Target’s rollback on diversity, equity and inclusion initiatives is raising questions about the retail giant’s philanthropic ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...

The recent U.S. Food and Drug Administration approval for Eli Lilly and Co.'s Omvoh, a new therapy to treat Chron's disease ...

Tectonic Therapeutic (TECX) plunges as Eli Lilly (LLY) ends a mid-stage trial for its kidney drug volenrelaxin which is similar to TECX's lead drug TX45. Read more here.

DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating on January 21.Invest with Confidence: Follow ...

In a report released yesterday, Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report), with a price ...

Investing.com -- Shares of pharmaceutical giant Eli Lilly (NYSE:LLY ... the treatment of adults with overweight or obesity. The company's executive vice president for Development, Martin Lange ...